Logo Image
|Articles|June 1, 2008

Pharmaceutical Executive

  • Pharmaceutical Executive-06-01-2008
  • Volume 0
  • Issue 0

Mary Szela, Abbott

S

ONE TO WATCH:

Mary Szela SVP, Pharma Operations, Abbott

With more than 20 years at Abbott, Szela, age 45, is making her way through the ranks. She started her career at the University of Illinois Hospital, and then headed up Abbott's hospital products division (now Hospira). Since joining the pharma side, she's led commercialization on several brands, including Humira, and in 2007 was named to lead the Rx biz.

Articles in this issue

over 18 years ago

Mightier Than the Sword

over 18 years ago

Keeshia Muhammad, Teva Specialty Pharmaceuticals

over 18 years ago

Eric Floyd, Cephalon

over 18 years ago

Kimberly Park, Vice President Sales and Marketing, PriCara, Ortho-McNeil Janssen Pharmaceuticals

over 18 years ago

Nancy Phelan, Wyeth

over 18 years ago

Tightening the Chain

over 18 years ago

Kurt Graves, Vertex

over 18 years ago

Wendy Niebler, Shire

over 18 years ago

Perfectly Imperfect

over 18 years ago

Relaunching Reform

Related to this article

View more
Pharmaceutical Executive Daily
Pharmaceutical Executive Daily: FDA Approves Fayuvi
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Read more
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance.
Addressing MFN Innovation Concerns
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.
Read more